

Paper No. _____
Filed: June 3, 2016

Filed on behalf of: Mylan Pharmaceuticals Inc.
By: Steven W. Parmelee
Michael T. Rosato
Jad A. Mills
WILSON SONSINI GOODRICH & ROSATI
701 Fifth Avenue, Suite 5100
Seattle, WA 98104-7036

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner,

v.

ALLERGAN, INC.,
Patent Owner.

Case No. IPR2016-01127
Patent No. 8,685,930

**PETITION FOR INTER PARTES REVIEW OF
U.S. PATENT NO. 8,685,930**

TABLE OF CONTENTS

	<u>Page</u>
I. INTRODUCTION	1
A. Brief Overview of the '930 Patent	2
B. Brief Overview of the Prosecution History	3
C. Brief Overview of the Scope and Content of the Prior Art.....	6
i. U.S. Patent No. 5,474,979 to Ding <i>et al.</i> ("Ding '979," EX1006)	6
ii. Sall <i>et al.</i> , <i>Two Multicenter, Randomized Studies of the Efficacy and Safety of Cyclosporine Ophthalmic Emulsion in Moderate to Severe Dry Eye Disease</i> , 107 OPTH. 631 (2000) (EX1007).....	8
iii. A. Acheampong <i>et al.</i> , <i>Cyclosporine Distribution into the Conjunctiva, Cornea, Lacrimal Gland, and Systemic Blood following Topical Dosing of Cyclosporine to Rabbit, Dog, and Human Eyes</i> , 2 LACRIMAL GLAND, TEAR FILM, AND DRY EYE SYNDROMES 1001 (1998) ("Acheampong," EX1008).....	8
D. Brief Overview of the Level of Skill in the Art	9
II. GROUNDS FOR STANDING	10
III. MANDATORY NOTICES UNDER 37 C.F.R. § 42.8	10
IV. STATEMENT OF THE PRECISE RELIEF REQUESTED FOR EACH CLAIM CHALLENGED.....	12
V. STATEMENT OF NON-REDUNDANCY	12
VI. CLAIM CONSTRUCTION	13
A. "buffer"	13
B. "substantially no detectable concentration"	13

C.	“therapeutically effective”	14
VII.	BACKGROUND KNOWLEDGE IN THE ART PRIOR TO SEPTEMBER 15, 2003	15
VIII.	DETAILED EXPLANATION OF GROUNDS FOR UNPATENTABILITY	20
A.	[Ground 1] Claims 1-36 are Anticipated under 35 U.S.C. § 102(b) by Ding ’979	20
i.	Claims 1-10, 12-22, 24-34, and 36	20
ii.	Claims 11, 23, and 35	27
B.	[Ground 2] Claims 1- 36, are Obvious under 35 U.S.C. § 103 over Ding ’979 and Sall	38
i.	Claims 1-10, 12-22, 24-34, and 36	38
ii.	Claims 11, 23, and 35	41
C.	[Ground 3] Claims 11, 23, and 35 are Obvious under 35 U.S.C. § 103 over Ding ’979, Sall, and Acheampong	45
IX.	OBJECTIVE INDICIA OF NON-OBVIOUSNESS: NO UNEXPECTED RESULTS.....	47
A.	No Unexpected Results	47
B.	No Evidence of Commercial Success	57
C.	No Industry Praise.....	59
D.	No Long-Felt, Unmet Need.....	59
E.	No Failure of Others.....	60
X.	CONCLUSION.....	60
XI.	CERTIFICATE OF COMPLIANCE	62
XII.	PAYMENT OF FEES UNDER 37 C.F.R. §§ 42.15(A) AND 42.103	63
XIII.	APPENDIX – LIST OF EXHIBITS	64

I. INTRODUCTION

Mylan Pharmaceuticals Inc. (“Petitioner”) requests review of U.S. Patent No. 8,685,930 to Acheampong *et al.* (“the ’930 patent,” EX1001) that issued on April 1, 2014. PTO records indicate the ’930 patent is assigned to Allergan, Inc. (“Patent Owner”). This Petition demonstrates that there is a reasonable likelihood that claims 1-36 of the ’930 patent are unpatentable for failure to distinguish over asserted prior art. Additional petitions are being filed to address related patents that are assigned to Patent Owner. All challenged patents are continuations from the same family and are terminally disclaimed over one another. The patents claim an ophthalmic emulsion for the treatment of overlapping ocular disorders, or conventional methods of administering the emulsion.

In particular, the ’930 patent claims a topical ophthalmic emulsion for treating dry eye disease, such as keratoconjunctivitis sicca (“KCS”), which contains 0.05 percent by weight (“%”) cyclosporin A (“CsA”), 1.25% castor oil, and other standard emulsion ingredients in a combination well known in the art. EX1001, 14:41-16:49. In fact, each element of the emulsion, including the claimed CsA and castor oil percentages and preferred ratios for combining them, was disclosed in a single prior art reference (Ding ’979) for use in topical ophthalmic emulsions to treat dry eye disease/KCS. Indeed, during prosecution of a parent application, applicants admitted that the claimed emulsion containing 0.05% CsA and 1.25% castor oil “is squarely within the teaching of the Ding [’979] reference” and “would have been obvious” to a person of skill in the art at the time of the invention. EX1005, 0435; EX1002, ¶18.

Four years later, in prosecuting the '930 patent as a continuation application, applicants changed course and attempted to withdraw these admissions. EX1004, 0007. They argued that data collected *after* their earlier admissions established patentability because of an alleged unexpected result that the emulsion was “equally or more therapeutically effective for the treatment of dry eye/keratoconjunctivitis sicca than the formulation containing 0.10% by weight cyclosporin A and 1.25% by weight castor oil.” EX1004, 0007, 0195; EX1002, ¶¶20-22. But the supposed “unexpected results” are weak, at best, and fail to rebut the strong evidence of obviousness. The data relied upon by applicants lack scientific parameters necessary to demonstrate statistical significance and materiality and, in many cases, appear to be copies of previously published graphs from a 102(b) prior art reference, Sall. Thus, Patent Owner’s cited evidence does not support non-obviousness of the claims, and merely confirms that the results were expected in view of and were already disclosed in the prior art.

A. Brief Overview of the '930 Patent

The '930 patent has an earliest claimed priority date of September 15, 2003. Independent claim 1 recites an emulsion of 0.05% CsA in 1.25% castor oil, polysorbate 80, acrylate/C10-30 alkyl acrylate cross-polymer (“cross-polymer”) and water, wherein the topical ophthalmic emulsion is therapeutically effective in treating keratoconjunctivitis sicca. Independent claims 13 and 25 recite an identical emulsion but state respectively that it is “therapeutically effective in treating dry eye” or “therapeutically effective in increasing tear production” in the

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.